The financials
Spyre Therapeutics, Inc. by the numbers
For the full year FY2025, revenue was $0 and net income −$155M.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Operating income | −$42M | −$42M | n/a |
| Net income | −$36M | −$37M | n/a |
| Diluted EPS | −$0.35 | n/a | n/a |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q3 2024Total $0.00
Segment Latestyear on year
- Development Fee And Royalty$0.00$0.00year on year --